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Abstract 
In 1927, Guido Fanconi described a hereditary condition presenting panmyelopathy 
accompanied by short stature and hyperpigmentation, better known as Fanconi anemia (FA). 
With this discovery, the genetic and molecular basis underlying FA has emerged as a field of great 
interest. FA signaling is critical in the DNA damage response (DDR) to mediate the repair of 
damaged DNA. This has attracted a diverse range of investigators, especially those interested in 
aging and cancer. However, recent evidence suggests FA signaling also regulates functions 
outside of the DDR, with implications in many other frontiers of research. The majority of 
research regarding FA signaling and the cell cycle primarily investigates DNA damage repair and 
its role during S phase and replicative stress. Here we discuss the relevant roles of FA signaling 
and FANCD2 during M phase and its particular role in chromosome segregation, along with a 
novel FANCD2 interacting partner. 
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Chapter One: Literature Review 
1.1 Fanconi Anemia 
Fanconi anemia (FA) is a rare autosomal recessive disease affecting approximately 1 of every 
136,000 newborns [1]. Originally described by the Swiss pediatrician in 1927, Guido Fanconi, 
today FA provides insight into a number of biological mechanisms and medical conditions. 
Clinically, FA contributes to numerous health complications, including the early onset of aging, 
multi-organ congenital defects, bone marrow failure leading to pancytopenia, and a remarkably 
high predisposition to hematological and non-hematological malignancies [2]. Cells derived from 
FA patients display distinct patterns of chromosomal abnormalities, presenting tri- and quadri-
radial figures in the chromosome spread. Additionally, FA cells demonstrate deficiencies in DNA 
damage repair and are characterized by genome instability and hypersensitivity to DNA 
crosslinking agents, such as mitomycin C (MMC), diepoxybutane (DEB), and cisplatin [3].  
In the pursuit to understand FA and its symptoms, FA has become a unique genetic model system 
to study cancer etiology, especially in the field of DNA damage [4-6]. The cellular and organic 
changes shown in FA patients suggest that the signal transduction pathway(s) underlying FA may 
regulate organ development. Furthermore, FA-associated symptoms suggest that FA signaling 
acts as a regulatory network in governing a broad range of biological processes beginning at 
embryogenesis and progresses throughout the patient’s lifespan. 
 
1.2 The FA  Genes 
To date, twenty-two FA complementation groups (Table 1) have been described (FANCA /B /C 
/D1 /D2 /E /F /G /I /J /L /M /N /O /P /Q /R /S /T /U /V & /W) [1, 7-9]. All of these groups have 
been identified based upon biallelic germline mutations that cause the FA phenotype, with the 
exception of FANCB and FANCR (Rad51) [10, 11]. In trying to understand the nature of FA and its 
symptoms, many studies have shown that the FA genes and pathways are perturbed. 
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Subtype Alias FA patients  
(~ %) 
Chr. 
Location 
Protein 
Product (Kd) 
Known Key Features of 
the Protein 
Ub 
A FANCH 64 16q24.3 163 Core complex, 
Phosphorylated 
+ 
B  2 Xp22.2 95 Core complex + 
C  12 9q22.3 63 Core complex + 
D1 BRCA2 2 13q12-13 380 HR - 
D2  4 3p25.3 155, 162 ID complex, 
monoubiquitinated, 
incision, TLS, HR, S phase 
arrest 
+ 
E  1 6p21-22 60 Core complex + 
F  2 11p15 42 Core complex + 
G XRCC9 8 9p13 68 Core complex + 
I  1 15q25-26 150 ID complex, 
phosphorylated, 
monoubiquitinated 
+ 
J BACH1, 
BRIP1 
2 17q22-24 130 RecQ DEAH helicase 
family, HR, MMS, TLS, 
DSB repair 
- 
L POG, 
PHF9 
0.4 2p16.1 43 Core complex, the 
ubiquitin ligase (E3) 
+ 
M  0.1 14q21.3 250 DNA translocase activity, 
lesion recognition, core 
complex 
+ 
N PALB2 0.7 16q12.1 130 HR, DSB repair - 
O RAD51
C 
0.1 17q25.1 47 RAD51 paralog, HR, - 
P SLX4, 
BTBD1
2 
0.5 16p13.3 200 Scaffold protein, 
endonuclease, 
unhooking crosslink, TLS, 
Telomere maintenance 
- 
Q ERCC4, 
XFP 
0.1 16p13.12 101 Endonuclease, NER - 
R RAD51 0.1 15q15.1 45 HR - 
S BRCA1 0.1 17q21.31 220 HR -/+ 
T UBE2T <0.1 1q32.1 22.5 Ubiquitin-conjugating 
enzyme (E2); NER 
+ 
U XRCC2 <0.1 7q36.1 34 Involved in HR, Resolving 
D-loop structure 
- 
V REV7, 
MAD2L
2 
<0.1 1p31 24 Subunit DNA polymerase 
ζ involved in TLS 
- 
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W RFWD3 <0.1 16q23.1 ~90 The ubiquitin-protein 
ligase (E3)  
-/+ 
Table 1.1 Overview of the twenty-two Fanconi anemia complementation groups. Ub: 
Ubiquitination (required for monoubiquitination); DSB, double strand break; HR, Homologous 
recombination; ID complex, FANCD2-FANCI; MMR, mismatch repair; NER nucleotide excision 
repair; TLS, translesion DNA synthesis. 
 
1.3 The FA/BRCA Pathway 
Long standing evidence suggests that a common signaling pathway acts to prevent the 
manifestation of FA and FA-like phenotypes. Comprised of at least twenty-two FA gene-encoded 
proteins (Table 1), the aforementioned signaling pathway has been coined the FA pathway [12, 
13]. Additionally, this pathway is commonly termed the FA-BRCA pathway, as several FA genes 
also encode breast cancer (BRCA) susceptibility gene products (Table 1).  
Although the presentation of FA varies, dependent upon which FA gene(s) is mutated, the notion 
of a common signaling pathway involving the FA proteins is supported by the similarities in the 
clinical symptoms displayed throughout the FA-subtypes [1, 14]. Currently, in addition to the 
twenty-two FA proteins, the FA pathway consists of a number of FA associated proteins such as 
FAAP20/24/100, MHF1/2 (FAAP16/10) [15, 16], and numerous interacting partners including 
FAN1 [17-20], DNA polymerase eta [21] and REV1 [22].  
 
The canonical FA signaling pathway is often dissected into three parts. Part I, comprises the FA 
core complex along with FANCT (ubiquitin conjugating enzme-E2) and upstream regulators. The 
core complex mainly acts as an ubiquitin ligase-E3, utilizing FANCL as the catalytic unit to 
monoubiquitinate FANCD2 and its paralog FANCI at Lys561 and Lys523, respectively [23]. Thus, 
Part I consists of FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM, FANCT, FAAPs 
and others [24, 25] (Figure 1.1). Part II, the FA ID complex is comprised of FANCD2 and FANCI 
(Figure 1.1). Part III, the functional units downstream of Part II, contains DNA repair proteins that 
act in coordination following the activation/monoubiquitination of FANCD2/FANCI (Figure 1.1). 
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The pathway is comprised of helicases (FANCM/J), nucleases and/or their collaborators (FANCQ/ 
or P), other enzymatic proteins (FANCL/T/V for E3, E2 and polymerase activities respectively), 
complex/scaffold proteins (FANCA/B/C/D2/E/F/G/I/P), as well as proteins involved in specific 
DNA damage repair processes. 
 
 
Figure 1.1. Schematical representation of the canonical FA pathway. Activation of the FA/BRCA 
pathway can occur subsequently after replication stress, ICL, stalled replication forks, DNA 
damage and more to maintain genome stability or repair DNA damage. Part I) the FA proteins 
(FANCA, B, C, E, F, G, L, M, T and possibly I) along with FAAPs (FAAP 20/24/100 and MHF1/2) form 
the FA core complex. Part II) FANCD2 and its paralog FANCI, comprise the heterodimer FA ID 
5 
 
complex. Part III) downstream of Part-II, the remaining FA proteins. Monoubiquitinated FANCD2 
and FANCI can be deubiquitinated by USP1, thereby inactivating the pathway. Red arrows 
indicate the canonical FA pathway. Ub indicates monoubiquitination. 
 
1.4 FA Signaling and DNA Damage 
Constant exposure to endogenous and exogenous genotoxic agents can compromise genome 
stability, when the DNA damage response (DDR) is compromised [26]. Checkpoint mechanisms 
serve as a major regulatory function in governing the DDR and ensure the coordination of DNA 
repair proteins, which detect and repair DNA damage to protect cells from genome instability 
[26]. In these checkpoint systems, the activation of the ataxia telangiectasia-mutated (ATM) and 
ATM and Rad3-related (ATR) DNA repair pathways are well-recognized master responses to 
genotoxic stresses [27]. In the event of DNA damage, repair proteins perform various roles by 
sensing damaged DNA and repairing it. Alternatively, repair proteins initiate processes to 
eliminate damaged cells [28, 29]. The canonical FA pathway has been identified as an essential 
part of the DDR, and can be activated upon DNA damage, especially from DNA crosslinks or during 
DNA replication [30-34].  
Studies have consistently conferred that when the FA pathway is impaired, cells are 
hypersensitive to DNA damage, and unable to successfully repair damaged DNA. Following DNA 
damage, the FANCM-FAAP24-MHF complex has been shown to act upstream of the DDR as key 
components along with ATR in the detection of DNA damage, which initiates the signaling 
transduction pathways to promote the monoubiquitination of FANCD2 and its paralog FANCI [35-
37]. Earlier studies reporting ATM-dependent phosphorylation at S222 of FANCD2 provided 
further evidence for the role of FANCD2 in the DDR, especially in the S-phase checkpoint response 
[38, 39].  
 
FA signaling acts to promote all known mechanisms of DNA repair, which include DNA interstrand 
crosslink (ICL) repair, homologous recombination (HR), nucleotide excision repair (NER), 
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translesion synthesis (TLS) repair, and Holiday junction (HJ) resolution [40]. FANCD2 can also 
regulate and cooperate the function of nucleases, enzymes responsible for unhooking the 
crosslinks in the early phase of DNA crosslink repair such as FANCP (SLX4) [41] and FAN1 [41, 42]. 
Recently, crosslink repair has also been implicated in the involvement of NER, with the 
emergence of FANCQ (XFP/ERCC4) and novel functions of FANCM and FANCT [7, 43-45]. In the 
later phases of crosslink repair, HR and/or non-homologous end joining (NHEJ) is proposed to 
correct errors left or generated from TLS to fully ensure genome integrity [32]. Although NHEJ is 
not as accurate as HR in maintaining the integrity of the genome, both repair mechanisms are 
essential and act in synergy, involving FANCS, FANCO, FANCD1/2 [46, 47]. Furthermore, FANCD2 
appears to also provide a platform for DNA repair proteins to function, such as in the case of CtIP 
in ICL repair [48]. Moreover, FA signaling modulates the function of proteins involved in mismatch 
repair (MMR) that do not directly participate in the course of DNA crosslink repair [49].  
 
1.5 Multifaceted Nature of FA Signaling 
FA signaling has been implicated in a number of regulatory processes from embryogenesis to 
aging [50]. Increasingly, with the continuous identification of interacting proteins and pathways, 
both crosstalk and regulatory functions are highly influential to achieve multiple FA signaling 
functions [7, 51]. Within the activation of FA signaling, numerous players have been recently  
recognized for their contributions, including Rad6 [52], Rad18 [52-54], BLM [55, 56], UHRF1 [57], 
MITF [58], Aurora A [59] and many more. Evidenced by crosstalk, research into FA has continually 
demonstrated that FA signaling may act as a regulatory network, in addition to the primary FA-
BRCA pathway [7].  
The canonical FA pathway (FA/BRCA pathway) is most commonly recognized for its roles in DNA 
damage repair. In contrast, non-canonical FA signaling independent of the FA/BRCA pathway 
have been reported to promote both DNA damage repair as well as roles independent from 
repair (Table 1.2) [50]. Currently, it is widely acknowledged that the FA and FA-associated 
proteins, such as FANCC, FANCA [60], FANCJ [61], FAAP24 [62], FANCI [63], etc., all possess 
pathway-independent roles in many cellular processes (Table 1.2). 
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The role of FA signaling in response to DNA damage and genome instability are likely to go hand 
in hand to the accelerated aging phenotype in FA patients. However, it is also suggested that the 
FA proteins are involved in both protecting and regulating telomere length [64]. This 
demonstrates the vast capacity of FA signaling, as FA cells have also been characterize to contain 
impaired telomeres [65]. Similarly, the FA pathway can regulate the cell cycle (discussed later in 
detail) either by responding to replicative stress, or through promoting mitotic function [66]. 
Distinct contrasting roles of FA signaling have also been observed in metabolism [40, 50], where 
the FA proteins are directly involved in mitochondria function [67, 68], as well as protecting cells 
from aldehydes [69]. As the former would stimulate non-canonical FA signaling and the latter 
would appears to activate the canonical FA pathway more favorably in response to the DNA 
damaging and carcinogenic properties [69-71]. 
 
FA signaling acts in a cell context-dependent manner, with the net cellular effects derived from 
the FA pathway and FA pathway-free functions [50]. Conversely, in the event that the FA pathway 
is inactivated, a new FA signaling function has been reported [72], rather than many of the clinical 
issues discussed above. 
 
FA Proteins    Involved in DNA damage 
 
Involved in other cellular processes 
FANCA   
 
 
 CD40 signaling pathway; cell proliferation; 
inflammatory response; T cell differentiation; 
Sequence-specific DNA binding transcription factor 
activity 
FANCB DNA damage repair 
(not entirely dependent on the 
FA core complex) 
 
FANCC TP53 Regulation of DNA Repair 
Genes 
Generic transcription pathway; Gene expression; 
Diabetes 
FANCD1 DNA damage repair,  
(not entirely dependent on the 
monoubiquitinated D2/I) 
Cell cycle regulation; meiotic recombination; 
Presynaptic phase of homologous DNA pairing and 
strand exchange; Resolution of D-loop structures 
FANCD2 The HHR6 signaling pathway; 
The ATM signaling pathway; 
DNA damage repair; TP53 
Replication:  
    Replication-origin firing, Stalled replication forks;  
Mitochondria function; gene expression;  
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regulation of DNA Repair 
Genes; MiRNA regulation of 
DDR  
FANCE/F/G DNA damage repair 
(not entirely depending on the 
FA core complex) 
 
FANCI The ATR signaling pathway; 
TP53 regulation of DNA Repair 
Genes; DNA damage repair  
Gene expression  
FANCJ DNA damage repair (not 
entirely dependent on the 
monoubiquitinated D2/I);  
G2/M DNA damage checkpoint 
Cell cycle regulation; Cytosolic iron-sulfur cluster 
assembly; P53 activity; Presynaptic phase of 
homologous DNA pairing and strand exchange; 
Resolution of D-loop structures  
FANCL DNA damage repair (not 
entirely dependent on the FA 
core complex)  
 
Ubiquitin mediated proteolysis 
FANCM ATR regulator, or a major 
sensor of the DDR 
Stalled replication forks 
FANCN DNA damage repair (HR) (not 
entirely dependent on 
monoubiquitinated FANCD2) 
Resolution of D-loop structures; Homologous DNA 
Pairing and Strand Exchange 
FANCO DNA damage repair (not 
entirely dependent on 
monoubiquitinated FANCD2) 
Meiosis; Resolution of D-loop structures; 
Megakaryocyte development and platelet production; 
Cell cycle 
FANCP DNA damage repair (not 
entirely dependent on 
monoubiquitinated FANCD2/I)  
Resolution of D-loop structures 
FANCQ DNA damage repair (DSB, NER) 
(not entirely dependent on 
monoubiquitinated FANCD2) 
Transcription 
FANCR DNA damage repair (HR) (not 
entirely dependent on 
monoubiquitinated FANCD2/I); 
ATM signaling   
Cell cycle; Meiosis; Rac1/Pak1/p38/MMP-2 pathway 
FANCS DNA damage repair (HR) (not 
entirely dependent on 
monoubiquitinated FANCD2/I);  
ATM signaling 
Transcription (ATF-2, E2F, FOXA1 transcription factor 
networks); Androgen receptor signaling pathway; 
Aurora A signaling; Cell Cycle Checkpoints; 
Deubiquitinating; Gene regulation 
FANCT DNA damage repair (not 
entirely dependent on 
monoubiquitinated FANCD2/I);  
 
Post-translational protein modification  
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FANCU DNA damage repair (not 
entirely dependent on 
monoubiquitinated FANCD2/I) 
Resolution of D-loop structures; Presynaptic phase of 
homologous DNA pairing and strand exchange 
FANCV TLS performed by POL1, POLK, 
REV1 or Zeta;  
post replication repair (not 
entirely dependent on 
monoubiquitinated FANCD2/I) 
Cell cycle regulation; Shigellosis; Oocyte meiosis; 
Endoderm Differentiation 
FANCW Ubiquitination of RPA (not 
entirely for the activation of 
the FA pathway) 
Ubiquitination;  
Mediation of p53 ubiquitination for its stability 
 
Table 1.2.  The FA pathway-independent roles played by the FA proteins [50]. 
 
1.6 Fanconi Anemia Complementation Group D2 
FANCD2 is the most evolutionarily conserved FA gene from lower eukaryotes to mammals [73], 
and shares approximately 20% similarity with invertebrates [6]. A key player within the FA 
pathway, FANCD2 also serve as important scaffold proteins to promote distinctive enzymatic 
activities [50]. FANCD2 is a 1,451 amino acid protein present in a non-ubiquitinated (155 kDa) 
and monoubiquitinated isoform (162 kDA) at basal (Table 1.1). Following activation of the FA 
pathway, indicated by the expression of monoubiquitination, the ratio of non-ubiquitinated to 
ubiquitinated FANCD2 shifts towards to the ubiquitinated form (Figure 2.1 A). In contrast to poly-
ubiquitination which tags a protein for proteasome degradation [74], FANCD2 
monoubiquitination promotes translocation, and is required for chromatin loading (Figure 2.1 B) 
[75]. Although incidence of FA patients, resulting from mutations in FANCD2 is relatively low, 
FANCD2 is considered a key central player in the FA signaling pathway, with over 80% of all FA 
mutations rendering the inability to monoubiquitinate FANCD2 (Table 1.1). Interestingly, in its 
non-ubiquitinated form, FANCD2 is also known to function via complex formation with BRCA1, 
FANCG and XRCC3 [76]. This demonstrates the elasticity of FANCD2 to perform distinctive 
regulatory roles. 
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Regulation of FANCD2: FANCD2-V1 & FANCD2-V2 
Recently, a new study analyzing the structure of FANCD2 concluded that FANCD2 exists in two 
variants, which present distinctive structural and functional characteristics [77]. The new FANCD2 
variant was named FANCD2-V2, in contrast to the long known FANCD2 variant, named FANCD2-
V1 for comparison. With this discovery, the FANCD2-V2 variant challenges the longstanding and 
thoroughly explored variant of FANCD2-V1, which until now has been acknowledged to be the 
only variant to exist. Due to structural and sequence similarity to FANCD2-V1, FANCD2-V2 was 
previously overlooked, differing by only 40 of 1471 AAs. Although it is still unclear the precise 
roles each variant undertakes, the ratio of FANCD2-V2/FANCD2-V1 expression is relatively higher 
in non-malignant cells/tissues and low stage tumors compared to their malignant counterparts. 
FANCD2-V2 thus appears to be more inclined to prohibiting the initiation of neoplastic 
transformation via its more potent tumor suppressive roles [77]. Therefore, transcriptional 
regulation (polyadenylation) of FANCD2 can have significant impact upon function, even with 
subtleties in structure. 
 
Regulation of FANCD2 monoubiquitination 
As we have already discussed, although it is evolutionarily conserved, FANCD2 function is 
dependent upon and subject to a number of regulatory mechanisms. In addition to 
polyadenylation, another transcriptional regulatory function, alternative splicing, has also been 
shown to significantly influence the activity of FANCD2 [78, 79]. Rather than directly impacting 
FANCD2 function, alternative splicing of FANCL creates the novel splice variant, FAVL [78, 79]. 
FAVL expression is heightened in malignancy and impairs FANCD2 monoubiquitination [78, 79]. 
This is achieved by sequestering FANCL into the cytoplasm for degradation, therefore, FANCL is 
unable to act as the catalytic unit to monoubiquitinate FANCD2. In our lab, cells with ectopically 
expressed FAVL to inactivate FANCD2 [79]. Similarly, mutant type (mt) cells carry a point 
mutation at Lys561 of FANCD2 in vitro, which also demonstrates impaired FANCD2 
monoubiquitination, compared to their wild type (wt) counterparts. 
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1.7 FA and Cancer 
Numerous studies have long indicated that the FA genes play regulatory roles extending beyond 
the protection from FA. Mutations in the FA genes have been of great interest in cancer biology, 
as individuals who carry these mutations inherently possess a much greater susceptibility to 
cancer [80]. Primarily, the FA genes function to protect individuals from cancer by effectively 
repairing damage DNA, as well as through other regulatory mechanisms, discussed later. 
However, studies show that in the absence of DNA damage, FA signaling can also function to 
promote replication fork stability [81, 82]. From the perspective that cancer is a genetic disease, 
it is believed to be caused by a series of mutations occurring in both germline and somatic cells 
[83-85]. Therefore, it comes as no surprise that mutations in the FA and FA associated genes lead 
to a compromised signaling, which is highly correlated to genome instability and tumorigenesis. 
[12]. 
 
Individuals who suffer from FA are prone to a number of different cancers such as acute 
myelogenous leukemia, breast cancer, squamous carcinoma of the head and neck, and cancers 
of gynecological system, skin, esophagus, liver and kidney [40]. Because of this, the median 
lifespan of FA patients range from 20-30 years [86]. In addition, as FA requires homozygous 
mutations, individuals who possess heterozygous mutations in any of the FA genes (with the 
exception of FANCB and FANCR) do not present the majority of FA symptoms, however, do carry 
a greater risk of developing cancers [86, 87]. Numerous studies have demonstrated a strong 
relationship exists between non-FA cancer patients carrying germline FA gene mutations and the 
development of a subset of human cancers [88-90]. Of particular interest, mutation in the breast 
cancer susceptibility genes (BRCA-related genes; FANCD1/S/N/J) are now often reported in 
relation to breast & ovarian cancer predisposition in women [91]. Although mutations in BRCA1/2 
(FANCD1/S) carries a considerably lower risk in males for breast cancer [91], a recent study has 
demonstrated the significance of BRCA2 mutations, as a risk factor for aggressive prostate cancer 
[92]. 
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Transformation of normal cells into cancer cells entail concerted genetic changes in many genes. 
Studies of non-FA cancer cell lines and human tissues have demonstrated that impaired FA 
signaling promotes tumorigenesis [78, 79, 93]. Whereby, the occurrence of mutations in FA genes 
related to the entire FA pathway has been reported to exist in thousands of non-FA 
tumor/cancers, even up to 52.8% of analyzed cases in bladder urothelial carcinoma (n=127) [87]. 
Data from The Cancer Genome Atlas shows that the rate of mutations to the FA pathway in other 
cancers vary depending upon the cancer (Figure 1.2). Whereas, the human genome project 
demonstrated that a considerable rate of impairment to the FA signaling pathway (near an 
approximate mean rate of 30%) was present in non-FA human cancers [87]. Importantly, the 
analysis of the rate of impairment to the FA pathway has been shown to be significantly and 
positively correlated to tumor stage [87]. Not to mention, epigenetic changes in the FA genes can 
also impair FA signaling functions, which increase tumorigenic potential [94, 95]. 
 
 
 
Figure 1.2. The relationship between the mutated FA pathway and human cancer. 
As mentioned previously, FA patients are known to have a high incidence of squamous cell 
carcinoma (43), in which tumor protein p63 (∆Np63) is highly expressed (48). A recent study has 
demonstrated that ΔNp63 has been reported to be elevated in FA cells carrying inactivated 
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FANCD2, but not in FANCD2 null cells or cells carrying wtFANCD2 (49). Therefore, these findings 
suggests a new role of FA signaling following the inactivation of FANCD2. Whereby, the Gain-of-
Function (GOF) phenomenon occurs following the inactivation of FANCD2. This adds a novel layer 
of complexity in our understanding of the roles of the FA signaling pathway in maintaining a 
variety of normal cellular processes to protect human cells in diseased states. 
 
Often in the context of cancer, DNA damage is depicted as a double-edge sword. On one hand, 
DNA damage is known to lead to genome instability and cancer. However, on the other hand, 
many therapeutic plans targeting cancer often rely on a compromised tumor DDR. Therefore, FA 
signaling in cancer not only protects normal cells from DNA damage but also tumor cells [40]. 
 
1.8 Overview of the Cell Cycle 
Cell division is an essential biological process in order for tissue growth, development and 
reproduction. The cell cycle describes a process of cellular division, which results in the formation 
of two genetically identical daughter cells from a single parent cell. This fundamental biological 
process is divided into four phases, gap 1 (G1), synthesis (S), gap 2 (G2), and mitosis (M). Over 
these four phases, genetic material must be faithfully duplicated and divided in pursuance of 
successful proliferation. Consequently, impaired cell cycle functions can result in aneuploidy, 
which often leads to apoptosis or malignant transformation [96, 97]. Interphases encompass the 
phases of G1, S and G2, by which cells exist in the majority of the time. During G1, cells increase 
their protein and organelle content in preparation for DNA replication.  
The transition from G1 to S phase signified the cells commitment to synthesize DNA from 2n to 
4n, and activate cellular replication machinery to replicate DNA. Following the successful 
completion of the S phase, cells enter G2, where they prepare for M phase. Alternatively, living 
cells can also enter irreversible senescence or quiescence (G0), rather than remaining in the cell 
cycle. The M phase of the cell cycle involves a series of stages to execute chromosomal and 
nuclear division, and cytoplasmic division (cytokinesis). These stages consist of prophase, 
prometaphase, metaphase, anaphase, and telophase and occur in sequential order, with the 
exception of cytokinesis, which is initiated during anaphase (Figure 1.3).  
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Initially (prophase), the chromosome condenses and shortens, following mitotic spindle 
assembly. Mitotic spindles are composed of microtubules (MTs), MT-associated proteins and 
motor proteins, which are organized by the centrosome, and required to ensure accurate 
chromosome segregation [98]. During early mitosis (prometaphase) the nuclear envelope breaks 
down, which allows the MTs to attach to the chromosomes via the kinetochore [98]. These events 
are regulated by the cytoskeletal motor proteins dynein and kinesin, which are responsible for 
intracellular cargo transport towards the minus and plus ends of the microtubule, respectively 
[99].  Following this, the chromosomes align at the equator and kinetochore MTs attach sister 
chromatids to the opposite poles (metaphase), which are then pulled and separated (anaphase). 
The nuclear envelope then re-assembles around the two sets of chromosomes, this occurs upon 
arrival to the spindle poles and centrosome (telophase). Simultaneously, during anaphase and 
telophase, cytokinesis occurs to ensure two daughter cells with a single nucleus are created. 
 
Figure 1.3. Overview of the cell cycle and the phases of mitosis, and cytokinesis 
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1.9 FA and the Cell Cycle 
Studies have reported dysregulation of the cell cycle in FA cells [100]. In addition, FA cells have 
high incidences of aneuploidy and micronucleation, often occurring as a result of chromosome 
missegregation [101]. In normal cells, the FA pathway is activated during the S phase of the cell 
cycle to respond to replicative stress [102]. In addition to genome instability [103], genetic 
models inhibiting FANCD2 monoubiquitination have also demonstrated deregulated cell 
proliferation/growth [104]. Following the impairment of FA signaling, the mechanistic 
consequences extend past deregulation in the DDR and aberrant replication. Indeed, the 
emerging roles of FA signaling may even encompass the M phase of the cell cycle [105-109].  
 
S phase and Replicative Stress 
FA signaling has recently also been acknowledged to play many regulatory roles during DNA 
replication, in which the entirety of cellular DNA must be faithfully duplicated to maintain 
genome stability. Furthermore, FA signaling is active in both non-stressed cells at the beginning 
of DNA synthesis and cells suffering from replicative stress during DNA synthesis [110-113]. To 
expand upon this, monoubiquitinated FANCD2 has been shown to be capable of functioning with 
initiators of replication to maintain a proper rate of DNA replication origin firing [111, 112]. In 
vitro, normal cells undergoing the loss of FANCD2 monoubiquitination can lead to a slow rate of 
replication origin firing, chromosomal abnormality and cellular aging, all hallmarks of cellular 
deregulation in patients with FA [111]. 
 
M phase 
During mitosis, the FA pathway is highly regulated via the degradation of FANCM, which not only 
reduces FANCD2 monoubiquitination [105], but also suggests further regulatory roles of FA 
signaling within the cell cycle. These studies appear to suggest that replicative roles of FA 
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signaling are unique to individual proteins within the FA pathway rather than a regulatory 
function of the whole pathway. 
During M phase, FA signaling is highly regulated via the degradation of FANCM. This occurrence 
not only reduces FANCD2 monoubiquitination but also implements further regulatory roles 
within the cell cycle [105]. In collaboration with BLM, FA signaling can promote proper 
chromosomal segregation at fragile sites [106, 107]. Additionally, FANCD2 has been found to be 
essential for the protection of chromosomal integrity [108]. To achieve this, FANCD2 acts in 
concert with FANCI and BLM to survive mitosis with acentric chromosomes in a DDR-independent 
manner [108]. Furthermore, FANCP has been reported to interact with Mus81 and others to 
promote appropriate chromosome segregation and to avoid mitotic catastrophe [109]. 
Moreover, crosstalk between FA signaling and other players expand the role of FA signaling in 
safeguarding chromosome stability during mitosis. In addition, the regulation of FA signaling by 
p21 (a cyclin-dependent kinase inhibitor) [114] and p53 [115] further supports the role of FA 
signaling in the regulation of cell proliferation. This possibly extends to all phases of the cell cycle, 
beyond the phases discussed. However, further research is required to validate this aspect of FA 
signaling, as it currently remains unclear. 
 
1.10 Nuclear Distribution Protein C 
The nuclear distribution protein C (NUDC) was originally identified in the filamentous fungus 
Aspergillus nidulans as a nuclear movement gene in the asexual reproductive cycle [116]. The 42 
kDa protein, NUDC, is highly conserved from fungi to human [117] and is essential for cell viability 
[118, 119], which eludes to its importance in cellular function. Mammalian homologues of the 
NUDC proteins include NudCL [120], and NudCL2 [121, 122], which all contain a p23 domain that 
is capable of binding with heat shock protein 90 (Hsp90) [123]. The nuclear distribution (nud) 
genes (Lis1/NUDF, NUDE, NUDA, NUDG and NUDK) encode components and regulators of the 
dynein/dynactin motor complex [123, 124]. Furthermore, NUDC is characterized as a stable 
ubiquitous protein, especially abundant in proliferative cells/tissues [125]. Although several 
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NUDC functions and interacting partners have been identified, there is still a great deal of 
unknown regarding this important gene/protein.  
 
NUDC in the M phase 
The exact role of NUDC in the M phase of the cell cycle is still somewhat unclear, however, NUDC 
protein expression has been detected to double during M phase [126]. Previous studies have 
evidenced NUDC in key events across multiple stages of mitosis, and cytokinesis [127]. In 
addition, NUDC has been observed to be localize at various locations during M phase (Table 1.3). 
The functions of NUDC through M phase is highly dependent upon protein interaction, complex 
formation and post-translational modifications. As such, NUDC localization to the mitotic spindle 
is critical for mitotic progression and requires interaction with echinoderm microtubule-
associated protein like 4 (EML4) [128].  
Although, understanding the impact of each role requires further investigation, NUDC and other 
nud proteins have been highly implicated in the regulation of dynein activity [120, 121, 127]. As 
previously mentioned, dynein is a cytoskeletal motor protein involved in chromosomal 
movement and spindle formation during M phase. In mammalian cells, NUDC interacts with 
Lis1/NUDF [129], kinesin-1 and dynein/dynactin to promote anterograde and retrograde 
transport along the MT [130]. Furthermore, NudCL, which shares similar sequence homology 
with NUDC, is suggested to promote dynein stability [120]. 
 
Phase of Mitosis NUDC Subcellular Localization 
Prophase MTOC 
Prometaphase MTOC, mitotic spindles 
Metaphase MTOC, mitotic spindles 
Anaphase Midzone of MTs 
Telophase Midzone of MTs 
Cytokinesis Midbody 
 
Table 1.3. NUDC localization during M phase [127, 131, 132]. Abbreviations: MTOC, microtubule 
organizing center; MTs, microtubules.  
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Other than its reported roles concerning dynein interaction, NUDC has also been observed to 
interact with Polo-like Kinase 1 (Plk1) independent of the dynein/dynactin complex [133]. Plk1 is 
essential in mitotic progression and performs multiple regulatory roles throughout the distinct 
phases of mitosis and cytokinesis [134, 135]. Studies have characterized that Plk1 phosphorylates 
NUDC at Ser274 and Ser326 [133]. Following Plk1 mediated phosphorylation, NUDC directs Plk1 
translocation to the outer plate of the kinetochore (Figure 1.4) [136]. In addition, this process is 
required for correct chromosomal alignment at the metaphase plate, chromosomal congression 
via Centromere Protein E (CENP-E) during prometaphase (Figure 1.4), and promotes kinetochore-
MT attachment [136]. 
 
Figure 1.4. Plk1 phosphorylates NUDC in M phase. Plk1 phosphorylation of NUDC leads to co-
localization of the Plk1-NUDC complex to the outer plate of the kinetochore. 
 
Post-translational modifications of mitotic proteins are known to regulate and drive M phase 
forward, with NUDC being no exception [137]. In addition to Plk1 [133, 136], Aurora B, a 
serine/threonine protein kinase implicated in chromosome condensation, segregation, and cell 
division [138, 139] has also been previously reported to phosphorylate NUDC [131]. 
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Immunoprecipitation (IP) experiments revealed that Aurora B interacts with NUDC at both the 
early and late phases of mitosis [131]. However, Aurora B mediated phosphorylation of NUDC at 
Thr40 occurs during cytokinesis to regulate intercellular bridges and cell abscission [131]. Cyclin-
dependent kinase 1 (Cdk-1) has also been suggested to phosphorylate NUDC [131], although, 
experimental data is currently lacking. 
NUDC deacetylation by histone deacetylase 3 (HDAC3) has also been reported to regulate M 
phase [132, 137]. NUDC acetylation occurs on Lys39, however, without deacetylation during M 
phase, chromosome alignment, segregation, and spindle formation is impaired [132]. Thus, 
NUDC has been observed to co-localize with HDAC3 during prometaphase and metaphase on the 
mitotic spindles [132].  Furthermore, NUDC deacetylation is also suggested to contribute to 
promote M phase progression [132]. 
 
NUDC and tumorigenesis 
Mitosis is a heavily regulated process that requires precise coordination of molecular signals and 
events, in order to avoid genetic inaccuracies, which can lead to genome instability. Previously, 
NUDC has implicated in tumorigenesis and cancer, although the mechanism behind this is still 
unknown [123]. The rate of mutations in NUDC has been identified to be relatively low (below 
10% in various cancers) (Figure 1.5), this indicates NUDC functions may be impaired 
tumorigenesis irrelevant to gene mutations. In tumor and leukemia cells, NUDC is upregulated 
[140-142], however, overexpression of NUDC has shown to inhibit tumorigenesis of prostate 
cancer cells [141]. This phenomenon is suggested to be due to failures in cell division, as NUDC 
overexpression leads to cells with enlarged nucleuses, as well as bi-nucleated and multi-
nucleated cells (Figure 1.6) [141]. Similarly, these findings are consistent with other studies 
reporting NUDC overexpression reducing proliferation, and promoting aneuploidy and polyploidy 
[127].  
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Figure 1.5. The incidence of NUDC mutations in human cancer. Relatively low in various cancers, 
however, NUDC is subject to a number of post-transcriptional modifications, which may implicate 
NUDC function in tumorigenesis. 
 
Conversely, studies that downregulate or knockout NUDC have reported the mislocalization of 
dynein related proteins, impaired dynein functions, cell growth inhibition, lethality and/or 
multiple mitotic defects such as impaired kinetochore-microtubule attachment, elongated 
intercellular bridges, impaired spindle formation, chromosome miscongression, and more [120, 
130-133]. Aberrant NUDC expression, both overexpression and downregulation/knockout are 
shown to lead to cytokinesis failure and G2/M block, where cells exiting the S phase are unable 
to correctly divide (Figure 1.6) [143]. Therefore, NUDC may act similarly as a proto-oncogene to 
promote regular M phase functions. Further investigation is required to understand the 
evolutionarily conserved roles of NUDC in M phase and its relationship with tumorigenesis. As 
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mentioned above, NUDC function is not only dependent upon its expression, but also protein 
interaction(s) and posttranslational modifications. 
 
 
Fig 1.6. The role of NUDC in cell division, adapted from [143]. NUDC and its role in cell division; 
NUDC is an important regulatory protein during cell division. When NUDC function is impaired, 
this leads to events such as failure in cytokinesis and checkpoint inactivation of the G2/M phase 
block leading to aneuploidy/polyploidy, and senescence, apoptosis. 
 
 
 
 
22 
 
1.11 Aims of the Thesis 
The role of FA signaling in response to DNA damage and replicative stress have been subject to a 
great deal of investigation and is well characterized. However, the role of FA signaling in regards 
to the regulation of the cell cycle, specifically M phase, have yet to be elucidated. In recent years, 
FA signaling has clearly demonstrated its ability to regulate numerous biological functions outside 
of the DDR. With the emergence of new FA signaling functions independent of the FA pathway, 
non-canonical FA signaling demonstrates great potential to uncover new roles of the FA genes. 
Furthermore, new understanding of the vast regulatory roles of FA signaling suggests that the FA 
proteins would also interact with previously unknown targets.  
Currently, with respect to the literature, the focus upon FA signaling is primarily related to its role 
in the DDR and replicative stress. However, researchers have exposed that FA signaling is involved 
in processes extending outside of the DDR, as well as all phase of the cell cycle. Therefore, the 
goal of this thesis is to investigate the role of FA signaling in relation to the M phase of the cell 
cycle. In addition, we aim to characterize the relationship between FANCD2 and NUDC, and 
validate their roles as M phase regulatory proteins. 
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 Chapter Two: Manuscript 
2.1 Abstract 
Fanconi anemia (FA) is a genetic disease resulting from germline mutations in any of the 22 FA 
genes. Recently, evidence has demonstrated that FA signaling regulates a vast number of 
biological processes including the cell cycle. However, current research regarding FA signaling 
and the cell cycle mainly revolves around the role of FA during S phase. Despite this, we believe 
that FA signaling governs all phases of the cell cycle, with individual FA proteins performing 
independent functions. Here, we report that FA complementation group D2 (FANCD2) interacts 
with the M-phase protein, nuclear distribution protein C (NUDC). Using MS/MS mass 
spectrometry analysis we identified a number of proteins between 38-52 kDa, which interact 
with FANCD2. In addition, through gel filtration, immunoprecipitation (IP) and 
immunofluorescence (IF) analysis, we validated this relationship between FANCD2-NUDC 
interaction. Furthermore, we demonstrated that FANCD2 plays an important role in chromosome 
segregation, which may be achieve via its interaction with NUDC. 
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2.2 Introduction 
Fanconi anemia (FA) is a rare genetic disease characterized by a number of congenital defects, 
bone marrow failure and an increased susceptibility to hematological and non-hematological 
malignancies [2]. To date, 22 FA genes (FANCA /B /C /D1 /D2 /E /F /G /I /J /L /M /N /O /P /Q /R 
/S /T /U /V & /W) have been identified, which comprises a vast signaling network that includes 
the FA-BRCA pathway as well as a number of non-canonical FA pathways [144]. Impairment to 
any of the FA genes/proteins have demonstrated detrimental effects that lead to an increased 
rate of gene mutations, aging and cancer [40, 145, 146]. Previously, FA signaling has been 
primarily characterized as an essential component in the repair of DNA damage, especially in 
interstrand crosslinks (ICLs) [5]. Although this still holds true, the discovery of many novel 
interacting partner has prompted an expanded understanding regarding the regulatory functions 
of FA signaling. In recent years, FA signaling has demonstrated that it performs roles related to 
DNA replication [111, 112], the cell cycle [100], mitochondrial function [68], and metabolism 
[104]. Similarly, many FA signaling functions are carried out to maintain genome stability and/or 
prevent tumorigenesis [40, 145, 147]. 
 
In the event of DNA damage or replicative stress the FA signaling pathway is activated [4]. 
Activation of the FA pathway is characterized by FANCD2 and FANCI monoubiquitination, which 
signals to the downstream functional units [6]. In addition, FANCD2 is the most evolutionarily 
conserved FA gene, and arguably the most important player within the FA pathway [148]. 
Recently, using MS/MS mass spectrometry we identified a number of interacting proteins 
between 38-52 kDa and FANCD2. Of interest, we identified nuclear distribution protein C (NUDC) 
at 42 kDa. NUDC is associated with the microtubule motor dynein/dynactin complex, and 
promotes the regulation of M phase [123, 124]. 
 
NUDC is a highly conserved protein from fungi to humans and belongs to the nuclear distribution 
(nud) gene family. In fungi, NUDC is required for nuclear distribution for asexual reproduction 
[116], and is also essential to cell viability [119]. Whereas in humans, NUDC functions to regulate 
mitosis and cytokinesis throughout various cellular sub-compartments and numerous interacting 
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proteins [127]. Additionally, NUDC is also prone to a number of post-translational modifications 
such as acetylation and phosphorylation to regulate mitosis and cytokinesis [133, 137]. Studies 
which have investigated impaired NUDC function, have reported defects in M phase, such as 
cytokinesis failure that led to micronucleation, and G2/M phase block, leading to nondisjunction 
[127, 141]. Furthermore, overexpression of NUDC has been shown to inhibit tumorigenesis in 
prostate cancer cells [141]. Despite this, the mechanism by which NUDC regulates M phase is still 
unclear. 
 
FA cells exhibit a high incidence of aneuploidy and micronucleation, with a high rate of bi- and 
multinucleated cells, chromosomal breaks at fragile sites, and DNA bridges during mitosis [100, 
149]. Research has implicated FANCD2 in genome surveillance, acting as a checkpoint 
mechanism, whereby irradiated FA fibroblasts enter into abnormal mitosis [150]. Previously, we 
identified a role of FANCD2 in chromosomal segregation (unpublished data). Whereas more 
recently, we demonstrated that inhibition of FANCD2 monoubiquitination via a reduction in 
FANCL activity influenced the proliferative rate of cells in vitro [79]. Therefore, we believe FA 
signaling governs all phases of the cell cycle, not only during replicative stress [144]. Similarly, the 
level of NUDC expression also correlates to the cell proliferation and chromosomal segregation 
in cells in vitro [141]. 
 
This study investigates the role of FANCD2 during M phase using a previously established cell 
system, involving FANCL knockdown leading to slow, medium and fast growing cells [79]. Here, 
we validated the proteomic interaction between FANCD2 and NUDC, and aimed to identify a role 
for FANCD2 in M phase to account for our previous observations in vitro. These studies for the 
first time suggest that abnormalities triggered by impaired FA signaling may be attributed to the 
loss of a functional link between FANCD2 and NUDC.  
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2.3 Materials and Methods 
Cell culture 
Colonic epithelial cells (CRL-1790), human embryonic kidney 293T cells, human bone 
Osteosarcoma Epithelial Cells (U2OS) cells, and human ovarian adenocarcinoma line (IGROV1) 
cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA).  Cells 
were grown in high glucose Dulbecco’s Modified Eagle Medium (DMEM), supplemented with 
10% fetal bovine serum (FBS) and 0.5% pen-strep. Cells were cultured in a humidified incubator 
contain 5% CO2 at 37oC, and subculture appropriately. As previously described [79], the slow, 
medium and fast cell system is derived from cells following FANCL knockdown. 
 
Antibodies and Chemicals  
NUDC, vinculin, RFP and IgG antibodies were purchased from Santa Cruz (Dallas, TX, USA). 
FANCD2 antibodies were obtained from NOVUS (Littleton, CO, USA). Flag and β-actin antibodies 
as well as mitomycin C (MMC), cisplatin, crystal violet solution, puromycin, blue dextran, and 
molecular weight markers used for gel filtration were purchased from Sigma (St. Louis, MO, USA). 
 
DNA Damage Interventions 
In this study, in order to induce DNA damage, cells were subject to various DNA damaging agents 
such as ultraviolet C (UVC), cisplatin, MMC and irradiation (IR). IGROV1 cells were treated with 
50 j/m2 UVC and harvested at 30 min and 2 h post treatment. The CRL-1790 cells were treated 
with 50 ng/ml MMC and harvested 11 d post treatment. U2OS cells received 10 Gy IR and were 
collected at 0, 4, 8, 24 and 36 h post IR. U2OS cells were treated with cisplatin at 4 μM/ml and 
were harvested at 36 h post treatment.   
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Protein Fraction Preparation 
As previously described [79], lysates were prepared from 293T cells and separated in cytoplasmic, 
nuclear and chromatin fractions as described in the protocols provided by the manufacturer 
(Pierce, Thermo Fish Scientific, Waltham, MA). 
 
Western Blot 
Lysates in SDS-lysis buffer were pipetted into 5% or 8% Tris-glycine SDS-polyacrylamide gels 
respectively, and separated via electrophoresis. Subsequently, proteins were transferred onto 
polyvinylidene fluoride (PVDF) membranes. Ponceau staining was used as quality control, and 
membranes were washed and blocked in 5% non-fat milk/PBS.  Membranes were incubated 
overnight at 4oC with primary antibody. Following this, membranes were washed with PBST and 
then incubated with secondary antibody for 1 h at room temperature. Immunoreactive bands 
were detected via enhanced chemiluminescence using Detection Reagent Luminol Enhancer and 
Detection Reagent 1 Peroxide Solution mixed in a 1:1 ratio (Pierce, Thermo Fish Scientific, 
Waltham, MA) and premium X-ray film (Phenix research products, Candler, NC, USA).  
 
Cell Proliferation 
As previously described [55], cells were equally plated at day 0. These cells were stained with 
crystal violet dye and formaldehyde at various time points and washed with PSB. Following a 
standard washing protocol, images were taken to analyze the cell confluence. Samples were 
analyzed in triplicates.  
 
Mass Spectroscopy 
The 8%-16% gradient SDS-PAGE gel was used to resolve FANCD2 elutes, which were prepared 
from CRL-1790 vector, slow, medium and fast cells. The protein gel was stained with Coomassie 
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blue and analyzed by MS/MS mass spectroscopy for peptide fragmentation at the Harvard 
Medical School Taplin Biological Mass Spectrometry Facility. 
 
Gel Filtration 
Gel filtration analysis was performed as previously described [21]. Nuclear extracts were isolated 
from CLR-1790 vector, slow, medium and fast cells. Cytoplasmic and nuclear fractionations were 
prepared with the NE-PER Nuclear and Cytoplasmic Extraction Reagent Kit (Pierce, Thermo Fish 
Scientific, Waltham, MA) as per the manufacturer’s instructions. The nuclear extracts were 
directly applied to a sepharose 6B column (Sigma) equilibrated with column running buffer 
containing 20 mM HEPES (pH 7.9), 200 mM NaCl, 1 mM dithiothreitol (DTT), 0.1 mM 
phenylmethylsulfonyl fluoride (PMSF), 5 mg/ml leupeptin, 2 mg/ml aprotinin, 0.1% NP-40 and 
5% glycerol. Fractions of 1 ml were collected and analyzed by SDS-PAGE and immunoblotting. 
2000 kDa blue dextran and 669 kDa thyroglobulin were used to determine the sizes of the 
fractions.  
 
TOPO-cloning 
Using the NCBI database, primers were designed via the PrimerQuest Tool specifically to target 
NUDC NM_006600.3, XM_017000094.1, XM_011540529.1, XM_017000095.1, XM_011540530.1 
and XM_017000096.1, in conjunction with the alignment software Serial Cloner 2-6 (Table 3.1). 
The TOPO TA kit was purchased from Invitrogen, and PCR products were obtained as per the 
manufacturer’s instructions. 10% 3M NaOac (pH 5.2) was added to the PCR product, along with 
isopropanol in a 1:1 ratio of the final concentration. Samples were frozen in -80oC for 10 min, 
thawed and spun down at 8,000 RPM. Following this, 200 µl 75% ethanol was used to wash, then 
precipitate DNA. Upon appropriate band detection, the protocol was continued as per 
manufacturer’s instructions. 1-10 ng of DNA was added to the DH5α competent cells, which were 
then incubated on ice for 30 min followed by 20 s of heat shock at 42oC, then incubated on ice 
again for 2 min. Following this, 1 ml LB medium was added to the cells and shaken at 225 RPM in 
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37oC for 1 h. Ampicillin and X-gal was spread onto the agar, followed by DH5α competent cell 
transformation, whereby, the plate(s) were incubate overnight at 37oC. Using the 
miniprep/midiprep kit purchased from Qiagen, we extracted plasmid DNA from bacteria as per 
the manufacturer’s protocol, and DNA concentration was quantified via spectrophotometer 
using the Nanodrop. 
 
 Forward Reverse 
NUDC X1 Primer 
Sequence 
5’- ATG ATC TCA AAC TAC AGA AAT 
GGC AGT -3’ 
5’-TCC CAG AGA GTGGGA AAG A -3’ 
NUDC X2 Primer 
Sequence 
5’- ATG GGC GGA GAG CAG GAG -
3’ 
5’-TCC CAG AGA GTGGGA AAG A -3’ 
Table 2.1 NUDC X1 and X2 primer sequences 
 
Ligation 
NUDC-RFP and pLKO.1-NUDC ligations were performed using T4 ligase, using a 3:1 ratio in 
molecular concentration. Alkaline phosphatase, calf intestinal (CIP) was applied to samples 
following plasmid cutting and purification, and samples were incubated for 1 h at 37oC to avoid 
dephosphorylation. The ligation reaction mixture (according to the protocol) was gently mixed 
and incubated at 16oC overnight, then heated for 10 min at 65oC. Once inactivated the reaction 
was chilled on ice and transformed in DH5α competent cells. 
 
Co-Transfection 
293T cells were cultured in DMEM containing 10% FBS. Plasmids and siRNA transient 
transfections were performed using Lipofectamine 3000 (Invitrogen) as per the manufacturer’s 
instructions. Once plasmids were added to the P3000 reagent, eppendorfs were vigorously 
vortexed and incubated for 5 min. Following this, the contents of the eppendorf was transferred 
into the eppendorf containing opti-medium and Lipofectamine 3000, which were mildly mixed 
and incubated for 25-30 min. Cells were washed with 1X PBS, prior to adding the transfection 
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mix. Following this, 16-24 h post transfection (pending cell condition), the opti-medium and the 
transfection mixture was replaced with DMEM and incubated at 37oC overnight. Subsequently, 
cells were split and harvested for analysis.  
 
Immunoprecipitation Assay 
Previously described [79], however, both scrapping and trypsinized collection methods were 
utilized. Cells were harvested and fixed in 37% formaldehyde for 3-5 min, glycine was added to 1 
M of the final concentration, and gently rocked for 10-15 min. Subsequently, cells were then 
washed and lysed. The lysates were incubated with monoclonal anti-flag, and NUDC antibodies, 
respectively, overnight at 4oC, and then incubation with protein A-sepharose (Invitrogen, Thermo 
Fisher Scientific, Waltham, MA) for 2 h. A beads were washed with medium IP wash buffer and 
then boiled in SDS-lysis buffer for 5 min. 
  
Gene knockdown by Lentiviral shRNA and Puromycin Selection 
Lentiviral transduction was performed as previously described [55]. A set of pLKO.1 plasmid 
containing shRNA targeting NUDC (NM_006600.3) (forward oligo; 5’-
CCGGAACGATTTGCCCAGCTCCTCTCGAGAGGAGCTGGGCAAATCGTTTTTTTG -3’ and reverse oligo; 
5’-AATTCAAAAAAACGATTTGCCCAGCTCCTCTCGAGAAGAGGAGCTGGGCAAATCGTT-3’) with the 
pLKO.1 empty vector (EV) was used to generate corresponding lentiviruses. 293T cells were 
transfected with packaging plasmid psPAX2, envelope pMD2G and hairpin-pLKO.1 vector and 
incubated at 37oC 5% CO2. Following an 18 h incubation, media was changed and incubation 
continued for another 24 h before the lentiviral particles were harvested via a 0.22 filter unit and 
this was repeated. U2OS cells were then infected at various titers by adding the collected virus 
to the cells (1/1, 1/2, 1/5, 1/10), and cells were incubated at 37oC overnight. 24 h post infection 
the media was changed again, which contained 0.5-4 μg/ml puromycin for puromycin selection. 
Following 1 w post puromycin selection, cells were harvested and western blot (WB) confirmed 
expression of NUDC. 
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Fluorescent Activated Cell Sorting (FACS) 
Cells were harvested and fixed in 75% ethanol and prepared for FACS analysis using propidium 
iodide staining (500 µl PI, 200 µl RNase (1 µg/ml), 10 ml 1X PBS) to measure DNA content. 
 
2.4 Results 
Monoubiquitination of FANCD2 in response to UVC treatment 
From this experiment, we observed that following UVC treatment FANCD2 monoubiquitination 
increased compared to the control samples (CON) and peaked 30 min post UVC treatment. 
Conversely, the expression of non-ubiquitinated FANCD2 appeared to be inversely related to the 
trend seen in the FANCD2-monubiquitinated form (Figure 2.1A). In addition, following UVC 
treatment, the expression of FANCD2 in the cytoplasm appeared to decrease, and was expressed 
higher in the chromatin compared to CON (Figure 2.1B). 
 
Figure 2.1. Western blot representation of FANCD2 activity. (A) Basal FANCD2 expression 
compared FANCD2 expression following UVC treatment (50 j/m2) at time points 30 min and 2 h 
post treatment. FANCD2-L (top band) represents the monoubiquitinated FANCD2 and FANCD2-S 
(bottom band) represents non-ubiquitinated FANCD2. (B) Localization of FANCD2 protein at basal 
compared to 2 h post UVC treatment (50 j/m2). 
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Slow, Medium and Fast Cells growth rates 
As shown in Fig 2.1 and viewed in [40, 144], FANCD2 is the center of FA signaling. To understand 
the molecular mechanisms underlying the abnormality triggered by impaired signaling, we 
decided to use inactivated FANCD2-containing cells to study cell proliferative defects caused by 
comprised FA signaling. The CLR cell set [79] was derived from reducing FANCL activity to inhibit 
FANCD2 monoubiquitination (Figure 2.2A). This contains vector (control) cells, FANCL↓ (slow) 
cells, FANCL↓ cells that have been growing for 2 years (medium) and FANCL↓ cells that have 
been growing for 3 years (fast). In our preliminary studies, we treated cells with 50 ng/ml 
Mitomycin C (MMC). Following 11 d post treatment, slow cells were detected at a lower cell 
count compared to their vector (control) counterparts. Similarly, medium and fast cells exhibit a 
higher cell count compared to slow cells. Moreover, fast cells exhibit a higher cell count 
compared to medium cells 11 d post MMC treatment (Figure 2.2B). 
 
Figure 2.2 FANCL knockdown in CLR-1790 cells. (A) Cell with FANCL knockdown exhibit a 
reduction in FANCL mRNA and FANCL protein expression. At basal, FANCD2 monoubiquitination 
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is reduced in FANCL knockdown compared to vector (control) cells. FANCD2-L represent 
monoubiquitinated FANCD2. FANCD2-S represents non-ubiquitinated FANCD2. (B) The 
proliferative response to MMC in CRL slow, medium and fast cells following 11 d post MMC 
treatment. 
 
Identifying FANCD2 and NUDC interaction 
Using the CRL cells previously described [79], FANCD2-IP analysis revealed an interaction 
between FANCD2 and protein(s) between 38-52 kDa, in cells treated with and without UVC 
treatment (Figure 2.3A). Following this discovery, using a proteomic approach, MS/MS mass 
spectroscopy identified eukaryotic translation initiation factor 4A1 (EIF4A1), RNA binding motif 
protein, X-linked (RBMX), 26S protease regulatory subunit 7 (PSMC2), regulator of chromosome 
condensation 1 (RCC1), nuclear distribution protein (NUDC) and vasodilator-simulated 
phosphoprotein (VASP) as interacting proteins of FANCD2 (Figure 2.3B). 
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Figure 2.3 FANCD2 interaction with proteins between 38-52 kDa. (A) SDS-PAGE gels represent 
FANCD2-IP in CRL slow, medium and fast cells with and without UVC treatment following 
coomassie blue staining. (B) MS/MS mass spectroscopy identifies a number of 38-52 kDa protein, 
which interact with FANCD2. 
 
Subsequently, our gel fractionation study demonstrated that the peak expression of NUDC for 
the CRL vector and CRL slow cells coincided with the same peak as FANCD2 (Figure 2.4) 
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Figure 2.4 FANCD2 and NUDC gel filtration. FANCD2 and NUDC peak at the same gel-filtration 
fractions prepared from the vector and slow cells but not in medium and fast cells. 
 
Whilst continuing to use the CRL cell set, endogenous immunoprecipitation (IP) experiments 
demonstrated that FANCD2 interacts with NUDC. However, this interaction appears to be 
diminished in fast cells, and in medium cells to a lesser extent compared to the vector and slow 
cells. No differences were observed between the vector and slow cells in FANCD2-NUDC IP 
(Figure 2.5). 
 
Figure 2.5 Endogenous FANCD2-NUDC IP. 
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TOPO Cloning NUDC 
Next, we aimed to confirm the interaction between FANCD2 and NUDC in situ. In order to achieve 
this, we cloned NUDC using the NCBI databased to designed primers for NUDC X1 and X2 (Table 
2.1)(Figure 2.6A). Using these primers, we successfully cloned NUDC (NM_00600.3), NUDC 
isoform X1 (XM_017000094.1) and NUDC isoform X4 (XM_011540529.1)(Figure 2.6C). Based 
upon the TOPO-NUDC map (Figure 2.6B), we used EcoRI and compared the detected bands via 
agarose gel electrophoresis (Figure 2.6C). Although we successfully cloned two novel isoforms of 
NUDC, we decided to continue our investigation using the NUDC clone most commonly reported 
in the literature. 
 
Figure 2.6 TA TOPO cloning and identification of NUDC & NUDC isoforms. (A) Visual 
representation of the NUDC gene and its variants from NCBI. (B) Map of the TOPO-NUDC 
construct, which include the respective cutting sites of EcoRI. (C) Image of a 1% agarose gel 
following electrophoresis, which represent the various sizes of DNA following EcoRI digestion. 
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NUDC-FANCD2 Interaction in Situ 
Subsequent to cloning NUDC, we aimed to purify the 1.2 kb band of NUDC (Figure 2.7A), which 
contained the NUDC gene based upon our construct map (Figure 2.6B). The RPF-vector was also 
cut, and both the RPF-vector and NUDC plasmids were purified and detected via agarose gel 
electrophoresis (Figure 2.7B). Once this was achieved, we ligated our RFP-vector with NUDC and 
successfully cloned RFP-NUDC. Following this, we picked up eight colonies and performed 
miniprep to extract the RFP-NUDC plasmid DNA. EcoRI was used to cut our samples, whereby, 
samples 2-8 expressed our band of interest (Figure 2.7C). Subsequently, one of the correctly 
identified miniprep samples was then cultured and midiprep was performed. 
 
Figure 2.7 RPF-NUDC purification and ligation detected via agarose gel electrophoresis. (A) 
Identification of the 1.2 kb band that contained the NUDC gene following EcoRI digestion. (B) RFP 
and NUDC purified and confirmed by their size (C) Miniprep samples following RFP-NUDC ligation 
and digested by the restriction enzyme HinIII. Blue arrow represent band of interest. 
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Following midiprep, the RFP-NUDC plasmid was transfected into 293T cells and imaged via a 
fluorescent microscope to detect the transfection efficiency (Figure 2.8A). In addition, the 
transfection efficiency was confirmed via WB (Figure 2.8B).  
Figure 2.8 RFP-NUDC transfection into 293T cells. (A) Transfection efficiency observed under a 
fluorescent microscope, RFP fluoresces red. (B) WB confirmation of transfection efficiency. NUDC 
is detected at ~43 kDa in both EV and RFP-NUDC transfection samples, however, in the RFP-NUDC 
sample a second band is also detected, which represents the NUDC that was transfected into the 
cell. RFP is only detected in the RFP-NUDC transfected sample. 
 
Concurrently, we obtained GFP-EV and GFP-FANCD2 plasmid samples from our lab and 
transfected them into 293T cells. Following this, we observed our cells under a fluorescent 
microscope to ensure an appropriate transfection efficiency (Figure 2.9). Initially, transfecting the 
GFP-wtFANCD2 plasmid into the 293T cells was not effective. To troubleshoot this, we cut GFP-
wtFANCD2 with Cla1 and purified the plasmid prior to the transfection. Despite this, the 
transfection efficiency was still higher in GFP-EV cells compared to GFP-WtFANCD2.  
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Figure 2.9 GFP-EV and GFP-wtFANCD2 transfection efficiency in 293T cells. The GFP tag in both 
EV and wtFANCD2 transfected cells exhibit a green fluorescence under the fluorescent 
microscope. 
 
Finally, to determine in situ interaction between FANCD2 and NUDC, we performed a co-
transfection and transfected both our GFP-wtFANCD2 plasmid and RFP-NUDC plasmid into 293T 
cells. This experiment successfully demonstrated that FANCD2 and NUDC interact using live 
fluorescent imaging, which determined an overlap in the cells expression of green and red to 
exhibit orange fluorescent cells (Figure 2.10). 
Figure 2.10 Fluorescent imaging suggests interaction between FANCD2 and NUDC. (A) RFP tag 
protein expressed in the cells exhibit red fluorescence. (B) GFP tag protein expressed in the cells 
exhibit green fluorescence. (C) Cells co-transfected with GFP-wtFANCD2 and RFP-NUDC observed 
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under live imaging. Blue arrows represent cells exhibiting a combination of a green and red 
(orange) fluorescence. 
 
Exogenous FANCD2-NUDC IP  
To further validate the previous observations between FANCD2 and NUDC interaction, we co-
transfected wtFANCD2, which contains a flag-tag protein, and RFP-NUDC into 293T cells. From 
this experiment, we detected Flag-FANCD2 pulldown in NUDC IP and Flag IP samples, as well as 
NUDC pull-down in Flag IP and NUDC IP samples (Figure 2.11). Together, this continues to support 
interaction between the FANCD2 and NUDC. 
 
Figure 2.11 Exogenous FANCD2-NUDC IP. Confirmation of exogenous protein interaction 
between transfected NUDC and wtFANCD2 containing a Flag tag protein. 
 
The biological effect of FANCD2 and NUDC in chromosomal segregation 
Previously, we identified that FANCD2 knockdown promoted abnormal chromosomal 
segregation in cells following IR via FACS analysis. Following IR, control cells were not observed 
to contain cells with abnormal octaploids (8N) until 24 h post IR, which decreased at 36 h post IR. 
However, in FANCD2 knockdown cells, immediately after IR, cells exhibiting 8N were observed as 
comparable to control cells 24 h post IR. In FANCD2 knockdown cells, a similar trend was 
observed, whereby, cells containing 8N peaked at 24 h post IR and this was reduced at 36 h post 
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IR. However, compared to their control counterparts, FANCD2 knockdown cells exhibited a much 
higher number of cells, which contained 8N (Figure 2.12). 
 
 
Figure 2.12 FACS analysis of control and FANCD2 knockdown cells post IR. 2N represents a diploid 
cell, which contains a single set of chromosomes. 4N represents a haploid cell containing 2 sets 
of chromosomes. 8N represents an octoploid cell, which is abnormal and indicates dysfunction 
in M phase. 
 
Similarly, as NUDC is involved in M-phase processes [127, 137] and is a binding partner of FANCD2 
we wanted to determine whether they performed similar biological functions with respect to 
chromosomal segregation. Therefore, via a lentivirus delivery system we aimed to silence NUDC. 
To achieve this, we first ligated our NUDC oligo with the pLKO.1 TRC-cloning vector and 
transformed the ligation mixture into competent bacteria. Five colonies were picked up and 
cultured, before performing miniprep. Following this, EcoRI and NBEI were used to digest our 
samples, through which samples 1, 4 and 5 expressed our band of interest (Figure 2.13A). 
Similarly, sample 1 was sent off for sequencing, which identified a 100% match to our oligo 
template (sequence 1) (Figure 2.13B). Thus, sample 1 was further cultured and midiprep was 
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performed. Likewise, EcoR1 and NBE1 was used to cut the sample and agarose gel 
electrophoresis identified the same band of interest (Figure 2.13C). 
 
 
Figure 2.13 pLKO.1-NUDC ligation. (A) Miniprep samples of potential pLKO.1-NUDC colonies cut 
with EcoR1 and NBE1. (B) Midiprep sample of Sample 1 cut with EcoR1 and NBE1. (C) Sample 1 
set for sequencing, to confirm correct pLKO.1-NUDC ligation and plasmid. 
 
As described above, we infected U2OS cells with a lentivirus, designed to silence NUDC. Cells 
infected with a 1/1 titer of the lentivirus had very high levels of cell death and did not continue 
to proliferate. Therefore, we diluted our infection medium to 1/2, 1/5, and 1/10 titer. Puromycin 
treatment at 1 µg/µl for 1-2 w confirmed U2OS cells were infected using the puromycin selection 
marker, according to the pLKO.1 puro with shRNA construct map (Figure 2.14A). Following our 
transfection of the 293T cells, these cells were immediately collected. WB analysis demonstrated 
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that NUDC expression was lower in these cells compared to the EV control infected cells. 
However, stable U2OS cells infected with the lentivirus targeting NUDC expressed lower levels of 
NUDC via WB compared to EV control and transiently transfected 293T cells (Figure 2.14B).  
 
Figure 2.14 Lentiviral transduction of pLKO.1 plasmids containing shRNA targeting NUDC. (A) 
Construct maps of pLKO.1 including puromycin resistance (B) WB detecting NUDC confirmed the 
success of NUDC knockdown via lentiviral transduction. 
 
Next, using the stable EV control and NUDC↓ cells we performed FACS analysis on cells treated 
with cisplatin compared to control. Although we did not observe significant differences between 
our conditions, a minor peak was observed in our sample 1/10 NUDC 36 h post cisplatin 
treatment (Figure 2.15A). However, further analysis of our results using a different channel we 
observed similarities in the 1/10 NUDC↓ cells similar to that of FANCD2↓ cells, following DNA 
damage (Figure 2.15B). 
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Figure 2.15 FACS analysis of U20S cells following DNA damage. (A) EV and NUDC knockdown cells 
were treated with cisplatin for 36 h and compared to untreated control cells via FACS analysis. 
(B) NUDC knockdown cells treated with cisplatin are compared to FANCD2 knockdown cells 36 h 
post IR via FACS analysis.  
 
In addition to investigating the role of NUDC on chromosomal segregation, we observed that cells 
infected with the lentivirus targeting NUDC proliferated at a slower rate initially, compared to 
the EV control cells. Therefore, we investigated the effects of growth via a proliferation assay, 
however, no significant differences were observed. 
45 
 
 
Figure 2.16 Proliferation assay in EV control cells compared to NUDC↓ cells. 
 
2.5 Discussion 
To better understand the role of FA signaling in tumorigenesis, we investigated the role of FA 
signaling in the regulation of M-phase. With the emergence of many new functions, it is now 
clear that FA signaling is far more complex than previously thought [144]. This confirms previous 
hypotheses made that an impaired response to DNA damage does not fully account for the FA 
phenotype, or its associated symptoms [144]. Therefore, further investigation is required in order 
to understand how FA signaling promotes genome stability and govern numerous biological 
processes throughout the lifespan. FA signaling largely acts to prevent the accumulation of 
genetic mutations during interphase, which includes G1, S and G2 [145]. However, our findings 
support the role of FA signaling, as a regulator of cell division. In addition, previous studies have 
observed that numerous FA proteins localize to important sites during cell division such as the 
centrosome and mitotic spindles [101].  
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Here, we report that FANCD2 interacts with the M-phase protein NUDC. Using MS/MS mass 
spectroscopy, we conducted an unbiased screening of FANCD2 and its functional units. Following 
this, a number of proteins were identified to associate with FANCD2, which included NUDC 
(Figure 2.3). To validate this interaction we first performed gel filtration analysis and found that 
in vector and slow cells, FANCD2 and NUDC shared similar peak expressions (Figure 2.4). This 
suggested that both proteins, along with their binding partners share a similar complex size, 
which would support interaction. Next, we performed numerous IP experiments and confirmed 
both endogenous (Figure 2.5) and exogenous interaction (Figure 2.11). We found that FANCD2 
antibodies pulled-down NUDC, and correspondingly NUDC antibodies were capable of pulling 
down FANCD2. Following this, we cloned NUDC based upon sequences provided by NCBI, and 
ligated NUDC with RPF. Next, using the GFP-NUDC plasmid, which was previously created in our 
lab, we performed a co-transfection and identified FANCD2-NUDC interaction in situ (Figure 
2.10). 
 
Once we validated the interaction between FANCD2 and NUDC, we next sought to investigate 
the functional significance. The cell system we previously designed involved cells with reduced 
FANCL activity. FANCL acts as the catalytic subunit to monoubiquitinate the FA ID complex [6]. 
Therefore, this unique system represents the inactivation of FANCD2 in vitro without using 
knockdown/knockout models. Initially, these FANCL↓ cells were labelled slow cells. As their 
name suggests, the slow cells proliferated at a slower rate compared to the CRL vector cells. Upon 
two and three years of continual passaging, we created medium and fast cells, respectively. This 
discovery alone provides insight in a potential role of FA signaling in proliferation, however, the 
rapid growth may also represent the progression towards a cancer phenotype. Interestingly, 
FANCD2 was observed to interact the most with NUDC in slow cells, where this interaction was 
progressively weakened in medium, fast, and vector cells (Figure 2.5). Further investigation will 
be required to understand this phenomenon, as our current data is somewhat unclear. 
 
As well as abnormal proliferation rates, we also identified abnormalities in FANCD2 knockdown 
cells following IR (Figure 2.12). The detection of a high number of octoploid cells containing 8N 
eludes to a number of roles for FANCD2 in M-phase. FANCD2 has been previously reported to act 
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as a spindle assembly checkpoint protein to arrest mitosis [145]. Alternatively, FANCD2 may also 
promote chromosome segregation following IR in order to replace damaged or apoptotic cells. 
Failure to successfully segregate duplicated chromosomes into separate cells represents a defect 
in either mitosis and/or cytokinesis, which leads to aneuploidy, a characteristic often observed 
in cancerous cells [151]. 
 
With the newfound discovery that NUDC interacts with FANCD2, we sought to establish whether 
the same consequences could be observed in a NUDC knockout/knockdown model. To achieve 
this, we infected U2OS cells in vitro, using a lentivirus delivery system to silence NUDC. Although, 
it was unclear whether these cells expressed NUDC at the protein level, the full concentration of 
the lentivirus infection lead to cell lethality, which was not observed in our EV control cells. This 
observation supports previous findings that suggest NUDC is essential for cell viability [119]. 
Simultaneously, we also infected cells with the same virus at a reduced viral titer. Following this, 
we observed that NUDC knockdown cells appeared to proliferate at a slower rate compared the 
EV control cells. However, when we completed our proliferation assay we were unable to observe 
any differences between our EV and NUDC knockdown cells (Figure 2.16). Finally, we did not 
observed the same effects in NUDC knockdown cells treated with cisplatin, a DNA crosslinking 
agent, compared to the irradiated FANCD2 knockdown cells (Figure 2.15A). Although, upon 
further analysis of our data we identified a similar trend amongst these conditions (Figure 2.15B). 
Therefore, we believe that FANCD2 may partly regulate error-free chromosomal segregation via 
its interaction with NUDC, however, further research is required to determine the functional 
significance of their interaction. 
 
In summary, this study provided evidence to add to the body knowledge, which suggests that FA 
signaling promotes the regulation of M phase. Here, we proposed that NUDC is a target of FA 
signaling to regulate the cell cycle. Although, we were unable to demonstrate the biological 
effects responsible by the interaction between FANCD2 and NUDC, we have provided sufficient 
data to clearly demonstrate their interaction. Furthermore, this study lays out a strong 
foundation to elucidate a novel mechanism(s) by which FANCD2 regulates cell division. 
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Chapter Three: Future Direction 
3.1 Future and Ongoing Work 
In this project we successfully cloned two novel isoforms of NUDC, which has not been previously 
performed (Figure 2.6). However, NCBI has identified an additional three isoform of the NUDC 
gene present in humans, which have yet to be clone. This research could lead to novel discoveries 
in the role of NUDC, as well as expand our findings by which FANCD2 interacts with NUDC. 
Previously, we have reported that FANCD2 exists in two variants, FANCD2-V1 and FANCD2-V2 
[152]. These two variants indicate distinct functions with respect to tumorigenesis [152], 
therefore, we have begun investigating whether or not NUDC preferentially binds to either 
FANCD2 isoform (Figure 3.1). 
 
Figure 3.1 FANCD2-V1-NUDC and FANCD2-V2-NUDC IP in Transfected 293T cells. GFP-D2V1 
represents cells transfected with GFP-FANCD2-V1 and RFP-D2V2 represents cells transfected 
with RFP-FANCD2-V2. Red arrows highlight pulldown (interaction). 
 
Furthermore, through bioinformatics and protein docking analysis we have determined five 
potential sites of FANCD2 and NUDC interaction (Figure 3.2). 
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Figure 3.2. FANCD2 is predicted to interact with NUDC amongst five possible regions. (A) 
Schematic representation of a series of deletions in NUDC, where FANCD2 may bind. (B) The 
molecular docking of FANCD2 and NUDC at the potential sites of interaction. 
 
Based upon these predictions, we designed five NUDC cDNA plasmids, which encode for wtNUDC 
and five mtNUDC proteins containing the deleted motifs 1-5, respectively. Using mutagenesis 
PCR to delete various AA regions in NUDC, we performed similar experiments outlined above in 
our study. To analyze the location of FANCD2-NUDC interaction we performed IF imaging of 293T 
cells co-transfected with GFP-FANCD2 and RFP-NUDC, and RFP-NUDC mutants 1-5 (Figure 3.3).   
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Figure 3.3. Immunofluorescence to highlight FANCD2-NUDC interaction. D1-D5 represents 
deletion 1-5 respectively. Green fluorescence represents GFP-FANCD2. Red fluorescence 
represents RFP-NUDC. 
 
Here, we have summarized the ongoing work described in our study to complete this project. In 
addition, to the characterization of the region by which NUDC interacts with FANCD2, we intend 
to demonstrate the biological effects of this interaction. This will be achieved by developing cell 
systems based upon the mtNUDC deletion plasmids. Once stable cells are developed, we will 
utilize xenograft models to investigate the role of FANCD2-NUDC interaction in tumorigenesis. 
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